AI in drug discovery

News

Novo Nordisk swells alliance with AI firm Valo Health

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.

News

Valo Health chief executive Brian Alexander, who is also CEO-Partner of Flagship Pioneering

Flagship-backed AI startup Valo shelves eye disease drug

Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug.

R&D

The AI revolution in pharma

The pharmaceutical industry is at a pivotal moment. Artificial intelligence (AI) is shifting from improving processes to reshaping disease treatment and care delivery.

News

Mulvany hits the reset button at BenevolentAI

The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.

News

Ken Mulvany speaking at a BenevolentAI event in 2018

BenevolentAI CEO steps down as founders make a comeback

Jörg Möller's sojourn as chief executive of BenevolentAI has come to an abrupt end after just nine months, as the company names co-founder Ken Mulvany as its executive chairman.

News